GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

Deloitte LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Having assessed the principal risks of the Company and other matters, the Directors are of the opinion that the current level of activity remains sustainable. The Directors in their considerations have included potential risks to demand and operational risks to supply throughout trade routes. The Directors have considered the Company's ability to continue as a going concern for a minimum of twelve months from the date of signing of these financial statements.”

Group structure

1. GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT LIMITED · parent
   1. GlaxoSmithKline Intellectual Property Development Limited 100% · UK

Significant events

• “The net increase in turnover from the previous year is due to an increase in third party royalty income and IP owner license income.”
• “The Company made a profit for the year of £1,843,399,000 ... mainly due to an increase in turnover, finance income and the reversal of impairment on investment in subsidiary during the year.”
• “During the year, the Company has recorded a reversal of impairment amounting to £394,067,000 relating to its investment in GlaxoSmithKline Intellectual Property Development Limited due to an increase in the cashflow forecast...”
• “On 1 June 2021, the MDL Court granted the Group's motion for summary judgment on federal pre-emption grounds... Plaintiffs appealed this decision and, on 9 January 2023, the United States Court of Appeals for the First Circuit affirmed the district court's decision in favour of the Group. There remains one state court case and four proposed class actions in Canada, which are not currently active and plaintiffs' counsel are seeking to discontinue.”
• “The Group received a letter dated 8 January 2024 from majority members of the US Senate Health, Education, Labor and Pensions ("HELP") Committee initiating an investigation into the pricing of inhalers...”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

5

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +7%

  £1,188,464,000 → £1,271,725,000

• Cash

  —

  Not reported

• Net assets

  +14.4%

  £12,812,679,000 → £14,656,078,000

• Employees

  —

  Not reported

• Operating profit

  +41.3%

  £1,005,657,000 → £1,421,058,000

• Profit before tax

  +34.5%

  £1,568,495,000 → £2,110,106,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers